Literature DB >> 21606943

A proposal for a simple and inexpensive therapeutic cancer vaccine.

Aude M Fahrer1.   

Abstract

In this essay, I propose a new method of treating tumours, using an old and inexpensive preparation, that I contend would be of considerable benefit to patients and their cancer management. My rationale for this treatment initially arose from recent advances in the understanding of dendritic cell function. (Dendritic cells are key cells of the immune system that are able to either turn on or turn off T-cell responses.) Evidence to support this approach is found in 100-year-old studies on the immunotherapy of cancer. Also, I draw on some remarkable, but little-known studies from the 1960s-1990s, demonstrating that the preparation has already been trialled in humans (although not intratumourally, as I propose), and is considered sufficiently safe to proceed with clinical trials in cancer volunteers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606943     DOI: 10.1038/icb.2011.42

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  2 in total

1.  Monocyte-derived dendritic cells: Emerging players in the antitumor immune response.

Authors:  Sabine Kuhn; Franca Ronchese
Journal:  Oncoimmunology       Date:  2013-10-09       Impact factor: 8.110

2.  Simple and effective bacterial-based intratumoral cancer immunotherapy.

Authors:  Christina S E Carroll; Erin R Andrew; Laeeq Malik; Kathryn F Elliott; Maurice Orange; Desmond Yip; Rachel Allavena; Aude M Fahrer; Moira Brennan; James Meyer; Alexander Hintze; Andrew A Almonte; Cassandra Lappin; Philip MacPherson; Klaus-Martin Schulte; Jane E Dahlstrom; Rohit Tamhane; Teresa Neeman; Elizabeth W Herbert
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.